296 related articles for article (PubMed ID: 14604745)
1. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States.
Bell CE; Botteman MF; Gao X; Weissfeld JL; Postma MJ; Pashos CL; Triulzi D; Staginnus U
Clin Ther; 2003 Sep; 25(9):2464-86. PubMed ID: 14604745
[TBL] [Abstract][Full Text] [Related]
2. Economics of pathogen inactivation technology for platelet concentrates in Japan.
Staginnus U; Corash L
Int J Hematol; 2004 Nov; 80(4):317-24. PubMed ID: 15615255
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets.
Lopez-Plaza I; Weissfeld J; Triulzi DJ
Transfusion; 1999 Sep; 39(9):925-32. PubMed ID: 10533816
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands.
Postma MJ; van Hulst M; De Wolf JT; Botteman M; Staginnus U
Transfus Med; 2005 Oct; 15(5):379-87. PubMed ID: 16202052
[TBL] [Abstract][Full Text] [Related]
5. [Single-donor (apheresis) platelets and pooled whole-blood-derived platelets--significance and assessment of both blood products].
Hitzler WE
Clin Lab; 2014; 60(4):S1-39. PubMed ID: 24779310
[TBL] [Abstract][Full Text] [Related]
6. Pathogen-reduced platelets for the prevention of bleeding.
Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
[TBL] [Abstract][Full Text] [Related]
7. Amotosalen: Allogeneic Cellular Immunotherapies system, INTERCEPT Plasma System, INTERCEPT Platelet System, S 59.
BioDrugs; 2003; 17(1):66-8. PubMed ID: 12534321
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates.
Corash L
Vox Sang; 1998; 74 Suppl 2():173-6. PubMed ID: 9704443
[TBL] [Abstract][Full Text] [Related]
9. Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model.
Prioli KM; Karp JK; Lyons NM; Chrebtow V; Herman JH; Pizzi LT
Appl Health Econ Health Policy; 2018 Dec; 16(6):889-899. PubMed ID: 30062464
[TBL] [Abstract][Full Text] [Related]
10. New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes.
Corash L
Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):549-63. PubMed ID: 11102276
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the economic value of the INTERCEPT blood system in Belgium.
Moeremans K; Warie H; Annemans L
Transfus Med; 2006 Feb; 16(1):17-30. PubMed ID: 16480436
[TBL] [Abstract][Full Text] [Related]
12. Addressing the risk of bacterial contamination in platelets: a hospital economic perspective.
Li JW; Brecher ME; Jacobson JL; Harm SK; Chen D; El-Gamil A; Dobson A; Mintz PD
Transfusion; 2017 Oct; 57(10):2321-2328. PubMed ID: 28703862
[TBL] [Abstract][Full Text] [Related]
13. [Bacterial contamination: should it be detected or inactivated?].
Cazenave JP
Transfus Clin Biol; 2007 May; 14(1):81-5. PubMed ID: 17521943
[TBL] [Abstract][Full Text] [Related]
14. I am the 9%: Making the case for whole-blood platelets.
Seheult JN; Triulzi DJ; Yazer MH
Transfus Med; 2016 Jun; 26(3):177-85. PubMed ID: 27170206
[TBL] [Abstract][Full Text] [Related]
15. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.
Kerkhoffs JL; van Putten WL; Novotny VM; Te Boekhorst PA; Schipperus MR; Zwaginga JJ; van Pampus LC; de Greef GE; Luten M; Huijgens PC; Brand A; van Rhenen DJ;
Br J Haematol; 2010 Jul; 150(2):209-17. PubMed ID: 20507310
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system - an update.
Seghatchian J; Tolksdorf F
Transfus Apher Sci; 2012 Apr; 46(2):221-9. PubMed ID: 22365926
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of screening the U.S. blood supply for West Nile virus.
Custer B; Busch MP; Marfin AA; Petersen LR
Ann Intern Med; 2005 Oct; 143(7):486-92. PubMed ID: 16204161
[TBL] [Abstract][Full Text] [Related]
18. Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply.
AuBuchon JP; Birkmeyer JD
JAMA; 1994 Oct; 272(15):1210-4. PubMed ID: 7933351
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
20. [Platelet concentrates from whole-blood donations (buffy-coat) or apheresis: which one to use?].
Lozano ML; Rivera J; Vicente V
Med Clin (Barc); 2012 May; 138(12):528-33. PubMed ID: 21807386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
